APPLICANT(S): CANAANI, Dan et

**EXAMINER:** 

al.

**SERIAL NO.:** 

09/975,300

**GROUP ART UNIT: 1627** 

FILED:

October 12, 2001

Attorney Docket No.: P-4393-US1

FOR.:

**GENETIC SCREENING METHODS** 

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

## INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§1.56, 1.97 and 1.98, this Information Disclosure Statement includes:

1.	Documents including patents, publications, and other information listed on the attached						
	Form PTO-1449 for consideration by the Examiner;						
2. 🔲	Form PTO-1449 which lists documents including patents, publications and other						
	information for consideration by the Examiner but in accordance with 37 C.F.R. 1.98(d)						
	does not include those documents which have been previously cited or submitted to the						
	Patent Office in the following prior application U.S. Serial No, filed						
	which is properly identified and relied on.						
3.	Other information for the Examiner's consideration which was cited in a communication						
	from a foreign patent office in a counterpart foreign application.						

The information herein cited is only in fulfillment of Applicant(s) duty of candor in disclosing all information brought to Applicant(s) attention. This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art". If it should be determined that any of the

APPLICANTS:

CANAANI, Dan et al.

SERIAL NO.:

09/975,300

FILED:

Page 2

October 12, 2001

listed documents do not constitute "prior art" under United States law, Applicant(s) reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant(s) further reserve(s) the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each and every document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application and is evidence that the Examiner has considered the document.

This Information Disclosure Statement is being filed:

I)	$\boxtimes$	Within three (3) months of filing the subject Application or entry of the							
subjec	subject Application into the national stage or before mailing of the first Office Action on								
the me	he merits whichever event occurs last pursuant to of 37 C.F.R §1.97 (b); or								
II)		After the period specified in (I) but before the mailing date of either a final							
Offici	al Actic	on under 37 C.F.R §1.113 or a notice of allowance under 37 C.F.R §1.311							
which	ever occ	curs first;							
	1.	The undersigned hereby states that each item of information listed on							
	the Fo	rm PTO-1449 was cited in a communication from a foreign Patent Office in a							
	counte	erpart foreign application not more than three (3) months prior to the filing of							
	this In	formation Disclosure Statement; or							
	2.	the undersigned hereby authorizes the Patent Office to charge the fee							
	in the	amount of \$180.00 under 37 C.F.R §1.17 (p) to Deposit Account 05-0649.							
III)		After the period in (I) and (II) but before the payment of the issue fee,							
	1.	The Undersigned hereby states:							
		a)							
		was cited in a communication from a foreign Patent Office in a counterpart							

APPLICANTS:

CANAANI, Dan et al.

SERIAL NO.: FILED:

09/975,300

October 12, 2001

Page 3

foreign application not more than three (3) months prior to the filing of this

Information Disclosure Statement; or

b) that no items of information contained in Form PTO-1449 was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. §

1.56(c) more than three months prior to the filing of this Information

Disclosure Statement; and

2. The Undersigned hereby authorizes the Patent Office to charge the Petition fee in the Amount of \$180.00 under 37 C.F.R §1.17 (p) to Deposit Account

05-0649.

**Except** for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 05-0649.

Respectfully submitted,

Mark S. Cohen

Attorney for Applicant(s) Registration No. 42,425

Dated: April 9, 2003

Eitan, Pearl, Latzer & Cohen Zedek, LLP.

10 Rockefeller Plaza, Suite 1001 New York, New York 10020

Tel: (212) 632-3480 Fax: (212) 632-3490

ے ہے۔ PTO/SB/08A (18-96) Approved for use through 10/31/99, OMB/0651-0031

Approved for use through 10/31/99. OMB 0651-0031

APR 2 1 2003 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	Substitute	e for form	1449A/PTO	FIENT & TRAD	C	complete if Known	1
				C TEAU	Application Number	09/975,300	W
INF	FORMA	TION	DISCLOS	SURE	Filing Date	October 12, 2001	11
ST	ATEME	ENT B	Y APPLIC	CANT	First Named Inventor	r CANAANI, Dan	11/12/
					Group Art Unit	1627	900
(use as many sheets as necessary)					Examiner Name		(
Sheet	1	Of	2		Attorney Docket Numb	per P-4393-US1	in the second

U.S. PATENT DOCUMENTS								
Examiner nitials*			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear			
• •	AA	5,168,062	Stinski, Mark F.	Dec 1, 1992				
	ВВ	5,625,048	Tsien, Roger Y. et al	Apr 29, 1997				
	СС	4,686,186	Sugden, William M	Aug 11, 1987				
•					70			
. <u> </u>								
	-				\$ 'O			
				9				
					3 4			
	-				3 1			
					50			
<del>.</del>	-							
					2			
					9			
<u>.                                    </u>	-							
	<del>                                     </del>			· · · · · · · · · · · · · · · · · · ·	· ·			
	<del>                                     </del>							
	<del>                                     </del>		· · · · · · · · · · · · · · · · · · ·					
	<del>                                     </del>							

FOREIGN PATENT DOCUMENTS									
			nPatent Doc		Name of Patentee or	Date of Publication of	Dance Columns Lines		
Examiner Initials*	Cite No. 1	Office <sup>3</sup> N	lumber <sup>4</sup> (if k	d Code⁵ (nown)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	-	
								[	
····									
				ļ					
								Ī	
<u> </u>	<u> </u>								

	Examiner Signature	Date Considered	
Police I	A A S TORREST TO THE PART OF THE	~ / / / / / / / / / / / / / / / / / / /	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

se type a plus		•	APR 2	Appropriate Approp	PTO/SB/08A (10-96) proved for use through 10/31/99. OMB 0651-0031 lark Office: U.S. DEPARTMENT OF COMMERCE nation unless it displays a valid OMB control number.
-	Substitu	ute for fo	om 1449B/PTO	Com	plete if Known
				Application Number	09/975,300
INF	ORMA	<b>1017</b>	N DISCLOSURE	Filing Date	October 12, 2001
STATEMENT BY APPLICANT			BY APPLICANT	First Named Inventor	CANAANI, Dan
				Group Art Unit	1627
(t	use as m	any sh	eets as necessary)	Examiner Name	Top
	12	of	Ι 2	Attorney Docket Number	P-4393-US1

		OTHER REPORT NON DATENT LITERATURE DOCUMENTS	
	<del></del>	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	<del></del>
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	DD	SIMONS A, DAFNI N., DOTAN I., ORON Y., CANAANI D., "Establishment of a Chemical Synthetic Lethality Screen	
		in Cultured Human Cells," Genome Research pg. 266 www.genome.org/cgi/doi/10.1101/gr.154201	
	EE	YATES, J., WARREN N. SUGDEN B., "Stable replications of plasmids derived from Epstein-Barr virus in various	T
		mammalian cells" Nature Vol. 313 2B February1985	
	FF	ZHU Z., GEERTRUIDA M., VELDMAN., COWIE A., CARR A., SCHAFFHAUSEN B., KAMEN R., "Construction and	
		Functional Characterization of Polyomavirus genomes that separately encode the three early proteins" Journal	
		of Virology, July 1984 p. 170-180 Vol. 51 1984	—
	GG	GONZALEZ J.E., NEGULESCU P.A., "Intracellular detection assays for high throughput screening"	$+ \overline{}$
		Current opinion in Biotechnology 1998, 9:624-631	
			1
	+-		
			<u> </u>
	:		
			-
			<del>                                     </del>
			#

Please type a plus sign (	-) inside this box → +		PTO/SB/08A (10-96)
Under the Paperwork Redi	action Act of 1995, no persons are required to	Approved for use through 10 Patent and Trademark Office: U.S. DEPART respond to a collection of information unless it displays a v	/31/99. OMB 0651-0031 MENT OF COMMERCE
Examiner Signature		Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.